Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 290

1.

Not all moderate disease is the same - Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity.

Pan Y, Norton S, Gwinnutt JM, Kearsley-Fleet L, Symmons DPM, Lunt M, Young A; BSRBR-RA Control Centre Consortium, Hyrich KL, Verstappen SMM.

PLoS One. 2019 May 20;14(5):e0215999. doi: 10.1371/journal.pone.0215999. eCollection 2019.

2.

A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis.

Kitas GD, Nightingale P, Armitage J, Sattar N, Belch JJF, Symmons DPM; TRACE RA Consortium.

Arthritis Rheumatol. 2019 Apr 15. doi: 10.1002/art.40892. [Epub ahead of print]

PMID:
30983166
3.

Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease.

Hope HF, Binkley GM, Fenton S, Kitas GD, Verstappen SMM, Symmons DPM.

PLoS One. 2019 Jan 17;14(1):e0201196. doi: 10.1371/journal.pone.0201196. eCollection 2019.

4.

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register.

Fagerli KM, Kearsley-Fleet L, Mercer LK, Watson K, Packham J, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2019 Jan 1;58(1):80-85. doi: 10.1093/rheumatology/key241.

5.

Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS).

Sergeant JC, Hyrich KL, Anderson J, Kopec-Harding K, Hope HF, Symmons DPM; RAMS Co-Investigators, Barton A, Verstappen SMM.

Arthritis Res Ther. 2018 Jul 13;20(1):147. doi: 10.1186/s13075-018-1645-5.

6.

Baseline patient reported outcomes are more consistent predictors of long-term functional disability than laboratory, imaging or joint count data in patients with early inflammatory arthritis: A systematic review.

Gwinnutt JM, Sharp CA, Symmons DPM, Lunt M, Verstappen SMM.

Semin Arthritis Rheum. 2018 Dec;48(3):384-398. doi: 10.1016/j.semarthrit.2018.03.004. Epub 2018 Mar 15.

7.

Long-term persistence with rituximab in patients with rheumatoid arthritis.

Oldroyd AGS, Symmons DPM, Sergeant JC, Kearsley-Fleet L, Watson K, Lunt M, Hyrich KL; BSRBR-RA Contributors Group.

Rheumatology (Oxford). 2018 Jun 1;57(6):1089-1096. doi: 10.1093/rheumatology/key036.

8.

Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study.

Bluett J, Sergeant JC, MacGregor AJ, Chipping JR, Marshall T, Symmons DPM, Verstappen SMM.

Arthritis Res Ther. 2018 Mar 20;20(1):50. doi: 10.1186/s13075-018-1544-9.

9.

Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.

Fagerli KM, Kearsley-Fleet L, Watson KD, Packham J, Contributors Group BR, Symmons DPM, Hyrich KL.

RMD Open. 2018 Jan 7;4(1):e000596. doi: 10.1136/rmdopen-2017-000596. eCollection 2018.

10.

Have the 10-year outcomes of patients with early inflammatory arthritis improved in the new millennium compared with the decade before? Results from the Norfolk Arthritis Register.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM.

Ann Rheum Dis. 2018 Jun;77(6):848-854. doi: 10.1136/annrheumdis-2017-212426. Epub 2018 Feb 23.

12.

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Silva-Fernández L, De Cock D, Lunt M, Low AS, Watson KD; BSRBR-RA Contributors Group, Symmons DPM, Hyrich KL.

Rheumatology (Oxford). 2018 Sep 1;57(9):1533-1540. doi: 10.1093/rheumatology/kex304.

13.

Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic.

Druce KL, Iqbal K, Watson KD, Symmons DPM, Hyrich KL, Kelly C.

RMD Open. 2017 Jul 13;3(1):e000473. doi: 10.1136/rmdopen-2017-000473. eCollection 2017.

14.

Reply.

Gwinnutt JM, Symmons DPM, Lunt M, Verstappen SMM.

Arthritis Rheumatol. 2017 Dec;69(12):2402-2403. doi: 10.1002/art.40311. Epub 2017 Nov 2. No abstract available.

15.

Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.

Bluett J, Jani M, Symmons DPM.

Rheumatol Ther. 2017 Dec;4(2):309-332. doi: 10.1007/s40744-017-0071-5. Epub 2017 Aug 14. Review.

16.

Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Lapraik C, Marshall T, Lunt M, Verstappen SMM.

Rheumatology (Oxford). 2017 Sep 1;56(9):1510-1517. doi: 10.1093/rheumatology/kex172.

17.

Twenty-Year Outcome and Association Between Early Treatment and Mortality and Disability in an Inception Cohort of Patients With Rheumatoid Arthritis: Results From the Norfolk Arthritis Register.

Gwinnutt JM, Symmons DPM, MacGregor AJ, Chipping JR, Marshall T, Lunt M, Verstappen SMM.

Arthritis Rheumatol. 2017 Aug;69(8):1566-1575. doi: 10.1002/art.40090. Epub 2017 Jul 10.

18.

Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab.

De Cock D, Birmingham L, Watson KD, Kearsley-Fleet L; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Rheumatology (Oxford). 2017 Apr 1;56(4):661-663. doi: 10.1093/rheumatology/kew493. No abstract available.

PMID:
28137762
19.

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA.

Jani M, Dixon WG, Kersley-Fleet L, Bruce IN, Chinoy H, Barton A, Lunt M, Watson K; BSRBR-RA*; BSRBR-RA Control Centre Consortium*, Symmons DP, Hyrich KL.

RMD Open. 2017 Jan 17;3(1):e000314. doi: 10.1136/rmdopen-2016-000314. eCollection 2017. Erratum in: RMD Open. 2017 Feb 23;3(1):e000314corr1.

20.

Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis.

Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL; British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) and the BSRBR Control Centre Consortium.

Ann Rheum Dis. 2017 Apr;76(4):654-660. doi: 10.1136/annrheumdis-2016-209784. Epub 2017 Jan 10.

21.

Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Symmons DPM, Noyce PR, Hyrich KL; BSRBR.

Rheumatology (Oxford). 2017 Apr 1;56(4):672-673. doi: 10.1093/rheumatology/kew454. No abstract available.

22.

Response to: 'Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?' by Nocturne et al.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AA, Dixon WG, Watson KD, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Feb;76(2):e4. doi: 10.1136/annrheumdis-2016-210631. Epub 2016 Dec 1. No abstract available.

PMID:
27934677
23.

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.

Kihara M, Davies R, Kearsley-Fleet L, Watson KD, Lunt M, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register.

Clin Rheumatol. 2017 Feb;36(2):241-250. doi: 10.1007/s10067-016-3485-5. Epub 2016 Dec 2.

24.

Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study.

van Wesemael TJ, Ajeganova S, Humphreys J, Terao C, Muhammad A, Symmons DP, MacGregor AJ, Hafström I, Trouw LA, van der Helm-van Mil AH, Huizinga TW, Mimori T, Toes RE, Matsuda F, Svensson B, Verstappen SM, van der Woude D.

Arthritis Res Ther. 2016 Dec 1;18(1):285.

25.

Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis.

Kearsley-Fleet L, McErlane F, Foster HE, Lunt M, Watson KD, Symmons DP, Hyrich KL.

RMD Open. 2016 Oct 7;2(2):e000273. eCollection 2016.

26.

HLA-DRB1 Amino Acid Positions 11/13, 71, and 74 Are Associated With Inflammation Level, Disease Activity, and the Health Assessment Questionnaire Score in Patients With Inflammatory Polyarthritis.

Ling SF, Viatte S, Lunt M, Van Sijl AM, Silva-Fernandez L, Symmons DP, Young A, Macgregor AJ, Barton A.

Arthritis Rheumatol. 2016 Nov;68(11):2618-2628. doi: 10.1002/art.39780.

27.

Association Between Genetic Variation in FOXO3 and Reductions in Inflammation and Disease Activity in Inflammatory Polyarthritis.

Viatte S, Lee JC, Fu B, Espéli M, Lunt M, De Wolf JN, Wheeler L, Reynolds JA, Castelino M, Symmons DP, Lyons PA, Barton A, Smith KG.

Arthritis Rheumatol. 2016 Nov;68(11):2629-2636. doi: 10.1002/art.39760.

28.

Smoking-Related Mortality in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study Using the Clinical Practice Research Datalink.

Joseph RM, Movahedi M, Dixon WG, Symmons DP.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1598-1606. doi: 10.1002/acr.22882. Epub 2016 Oct 6.

29.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765
30.

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.

Silva-Fernández L, Lunt M, Kearsley-Fleet L, Watson KD, Dixon WG, Symmons DP, Hyrich KL; British Society for Rheumatology Biologics Register (BSRBR) Control Centre Consortium.

Rheumatology (Oxford). 2016 Nov;55(11):2033-2039. Epub 2016 Aug 22.

31.

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.

32.

Cardiovascular risk and its modification in patients with connective tissue diseases.

O'Sullivan M, Bruce IN, Symmons DP.

Best Pract Res Clin Rheumatol. 2016 Feb;30(1):81-94. doi: 10.1016/j.berh.2016.03.003. Epub 2016 May 26. Review.

PMID:
27421218
33.

Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register.

Cook MJ, Diffin J, Scirè CA, Lunt M, MacGregor AJ, Symmons DP, Verstappen SM.

Rheumatology (Oxford). 2016 Sep;55(9):1601-9. doi: 10.1093/rheumatology/kew210. Epub 2016 May 24.

34.

Risk of Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor α: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Bruce ES, Kearsley-Fleet L, Watson KD, Symmons DP, Hyrich KL.

Rheumatology (Oxford). 2016 Jul;55(7):1336-7. doi: 10.1093/rheumatology/kew200. Epub 2016 Apr 26. No abstract available.

PMID:
27118877
35.

Primary care-based screening for cardiovascular risk factors in patients with psoriasis.

Rutter MK, Kane K, Lunt M, Cordingley L, Littlewood A, Young HS, Chew-Graham CA, Hilton R, Symmons DP, Griffiths CE.

Br J Dermatol. 2016 Aug;175(2):348-56. doi: 10.1111/bjd.14557. Epub 2016 Jul 12.

36.

Response to: 'Evaluation of the association between anticarbamylated protein antibodies and longitudinal course of functional ability in rheumatoid arthritis' by Ajeganova et al.

Humphreys JH, Symmons DP, Verstappen SM.

Ann Rheum Dis. 2016 Apr;75(4):e15. doi: 10.1136/annrheumdis-2015-208957. Epub 2016 Feb 18. No abstract available.

PMID:
26893487
37.

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis.

Low AS, Lunt M, Mercer LK, Watson KD, Dixon WG, Symmons DP, Hyrich KL.

Arthritis Rheumatol. 2016 Jun;68(6):1337-45. doi: 10.1002/art.39582.

38.

Patient-reported improvements in health are maintained 2 years after completing a short course of cognitive behaviour therapy, exercise or both treatments for chronic widespread pain: long-term results from the MUSICIAN randomised controlled trial.

Beasley M, Prescott GJ, Scotland G, McBeth J, Lovell K, Keeley P, Hannaford PC, Symmons DP, MacDonald RI, Woby S, Macfarlane GJ.

RMD Open. 2015 Feb 18;1(1):e000026. doi: 10.1136/rmdopen-2014-000026. eCollection 2015.

39.

Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register.

Humphreys JH, Verheul MK, Barton A, MacGregor AJ, Lunt M, Toes RE, Symmons DP, Trouw LA, Verstappen SM.

Ann Rheum Dis. 2016 Jun;75(6):1139-44. doi: 10.1136/annrheumdis-2015-207326. Epub 2015 Oct 6.

40.

Methodological Challenges When Comparing Demographic and Clinical Characteristics of International Observational Registries.

Verstappen SM, Askling J, Berglind N, Franzen S, Frisell T, Garwood C, Greenberg JD, Holmqvist M, Horne L, Lampl K, Michaud K, Nyberg F, Pappas DA, Reed G, Symmons DP, Tanaka E, Tran TN, Yamanaka H, Ho M.

Arthritis Care Res (Hoboken). 2015 Dec;67(12):1637-45. doi: 10.1002/acr.22661.

41.

Epidemiology research in rheumatology-progress and pitfalls.

Symmons DP.

Nat Rev Rheumatol. 2015 Nov;11(11):631-8. doi: 10.1038/nrrheum.2015.92. Epub 2015 Jul 7. Review.

PMID:
26150125
42.

Amyloid myopathy masquerading as polymyositis.

Moore S, Symmons DP, DuPlessis D, Chinoy H.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4):590-1. Epub 2015 Jun 29. No abstract available.

PMID:
26120960
43.

Do we need a disease-specific cardiovascular risk calculator for patients with rheumatoid arthritis?

Symmons DP.

Arthritis Rheumatol. 2015 May;67(8):1990-4. doi: 10.1002/art.39199. No abstract available.

44.

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era.

Morgan C, McBeth J, Cordingley L, Watson K, Hyrich KL, Symmons DP, Bruce IN.

Rheumatology (Oxford). 2015 Oct;54(10):1780-91. doi: 10.1093/rheumatology/kev105. Epub 2015 May 13.

45.

Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response.

Viatte S, Plant D, Han B, Fu B, Yarwood A, Thomson W, Symmons DP, Worthington J, Young A, Hyrich KL, Morgan AW, Wilson AG, Isaacs JD, Raychaudhuri S, Barton A.

JAMA. 2015 Apr 28;313(16):1645-56. doi: 10.1001/jama.2015.3435.

46.

Direct health costs of inflammatory polyarthritis 10 years after disease onset: results from the Norfolk Arthritis Register.

Nikiphorou E, Davies C, Mugford M, Cooper N, Brooksby A, Bunn DK, Young A, Verstappen SM, Symmons DP, MacGregor AJ.

J Rheumatol. 2015 May;42(5):794-8. doi: 10.3899/jrheum.140528. Epub 2015 Apr 1.

PMID:
25834202
47.

Psoriasis and the Risk of Major Cardiovascular Events: Cohort Study Using the Clinical Practice Research Datalink.

Parisi R, Rutter MK, Lunt M, Young HS, Symmons DPM, Griffiths CEM, Ashcroft DM; Identification and Management of Psoriasis Associated ComorbidiTy (IMPACT) project team.

J Invest Dermatol. 2015 Sep;135(9):2189-2197. doi: 10.1038/jid.2015.87. Epub 2015 Mar 5.

48.

Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts.

Humphreys JH, van Nies JA, Chipping J, Marshall T, van der Helm-van Mil AH, Symmons DP, Verstappen SM.

Arthritis Res Ther. 2014 Dec 4;16(6):483. doi: 10.1186/s13075-014-0483-3.

49.

How do we classify rheumatoid arthritis in established disease--can we apply the 2010 American College of Rheumatology/European League Against Rheumatism classification criteria?

Humphreys JH, Verstappen SM, Scire CA, Uhlig T, Fautrel B, Sokka T, Symmons DP.

J Rheumatol. 2014 Dec;41(12):2347-51. doi: 10.3899/jrheum.141443. No abstract available.

PMID:
25452179
50.

Has the severity of rheumatoid arthritis at presentation diminished over time?

Diffin JG, Lunt M, Marshall T, Chipping JR, Symmons DP, Verstappen SM.

J Rheumatol. 2014 Aug;41(8):1590-9. doi: 10.3899/jrheum.131136. Epub 2014 Jul 1.

Supplemental Content

Loading ...
Support Center